Early boost for Life Medical's anti-adhesion product:
This article was originally published in Clinica
Life Medical Sciences has taken an early, but important, step closer to becoming the first to gain US approval to market an anti-adhesion product for use in cardiac surgery. A US feasibility trial of the company's REPEL-CV bioresorbable adhesion barrier for reducing post-operative adhesion formation in cardiac surgical procedures has provided preliminary data to support the product's safety and effectiveness, says the Ocean Port, New Jersey firm. Life Medical has submitted the results and a proposed multicentre, pivotal clinical trial protocol to the FDA. The proposed trial is expected to form the basis for obtaining FDA approval to market the product.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.